ECSP077992A - Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms - Google Patents

Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms

Info

Publication number
ECSP077992A
ECSP077992A EC2007007992A ECSP077992A ECSP077992A EC SP077992 A ECSP077992 A EC SP077992A EC 2007007992 A EC2007007992 A EC 2007007992A EC SP077992 A ECSP077992 A EC SP077992A EC SP077992 A ECSP077992 A EC SP077992A
Authority
EC
Ecuador
Prior art keywords
compounds
inhibitors
tienopirimidine
tienopiridine
derivatives
Prior art date
Application number
EC2007007992A
Other languages
English (en)
Inventor
Michael David Gaul
Christian Andrew Baumann
Kevin Douglas Kreutter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP077992A publication Critical patent/ECSP077992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La invención esta dirigida a tienopirimidinas y tienopiridinas de fórmula I y fórmula IIen donde R1, R3, B, Z, Q, p, q y X son como se define en la presente, el uso de dichos compuestos como moduladores de proteína tirosina cinasa, particularmente inhibidores de FLT3, el uso de dichos compuestos para reducir o inhibir la actividad cinasa de FLT3 en una célula o un sujeto, y el uso de dichos compuestos para la prevención o tratamiento en un sujeto de un trastorno proliferante celular y/o trastornos relacionados a FLT3; la presente invención se refiere además a composiciones farmacéuticas que comprenden los compuestos de la presente invención y a métodos para el tratamiento de condiciones tales como cánceres y otros trastornos proliferantes celulares.
EC2007007992A 2005-06-10 2007-12-10 Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms ECSP077992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971005P 2005-06-10 2005-06-10
US74694106P 2006-05-10 2006-05-10

Publications (1)

Publication Number Publication Date
ECSP077992A true ECSP077992A (es) 2008-01-23

Family

ID=37074647

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007992A ECSP077992A (es) 2005-06-10 2007-12-10 Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms

Country Status (19)

Country Link
US (3) US20060281768A1 (es)
EP (1) EP1899355A1 (es)
JP (1) JP2008543759A (es)
KR (1) KR20080021126A (es)
AR (1) AR057063A1 (es)
AU (1) AU2006258049A1 (es)
BR (1) BRPI0613644A2 (es)
CA (1) CA2611587A1 (es)
CR (1) CR9650A (es)
EA (1) EA200800011A1 (es)
EC (1) ECSP077992A (es)
IL (1) IL187689A0 (es)
MX (1) MX2007015741A (es)
NI (1) NI200700311A (es)
NO (1) NO20080162L (es)
PE (1) PE20070070A1 (es)
TW (1) TW200716651A (es)
UY (1) UY29590A1 (es)
WO (1) WO2006135639A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US20090124610A1 (en) * 2006-04-25 2009-05-14 Gordon Saxty Pharmaceutical compounds
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
TW200924781A (en) * 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
WO2012131399A1 (en) 2011-04-01 2012-10-04 Astrazeneca Ab Therapeutic treatment
KR102001364B1 (ko) 2011-05-13 2019-07-22 어레이 바이오파마 인크. Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
MY191956A (en) 2014-05-15 2022-07-20 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3559006A4 (en) * 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
WO2020171646A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
CA3145391A1 (en) 2019-06-27 2020-12-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
WO2024248513A1 (en) * 2023-05-31 2024-12-05 Hanmi Pharm. Co., Ltd. Solid dispersion of myeloid kinome inhibitors and pharmaceutical composition comprising the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5932765A (en) * 1997-05-23 1999-08-03 Merck Patent Gesellschaft Mit Nitromethyl ketones, process for preparing them and compositions containing them
WO1999024440A1 (en) * 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
DE69934093T2 (de) * 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
TWI238824B (en) * 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
MXPA05001631A (es) * 2002-08-12 2005-08-19 Takeda Pharmaceutical Derivado de benceno fusionado y su uso.
EP1566379A4 (en) * 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators

Also Published As

Publication number Publication date
CR9650A (es) 2008-09-09
EP1899355A1 (en) 2008-03-19
US20090163710A1 (en) 2009-06-25
AR057063A1 (es) 2007-11-14
MX2007015741A (es) 2008-04-29
TW200716651A (en) 2007-05-01
BRPI0613644A2 (pt) 2011-01-25
KR20080021126A (ko) 2008-03-06
AU2006258049A8 (en) 2006-12-21
CA2611587A1 (en) 2006-12-21
AU2006258049A1 (en) 2006-12-21
NI200700311A (es) 2009-03-03
US20090143378A1 (en) 2009-06-04
NO20080162L (no) 2008-03-07
JP2008543759A (ja) 2008-12-04
WO2006135639A1 (en) 2006-12-21
IL187689A0 (en) 2008-08-07
US20060281768A1 (en) 2006-12-14
UY29590A1 (es) 2006-10-02
EA200800011A1 (ru) 2008-06-30
PE20070070A1 (es) 2007-03-08

Similar Documents

Publication Publication Date Title
CR9650A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
ECSP077997A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
CR9649A (es) Aminopirimidinas como modulares de cinasa
ECSP088573A (es) Triazolopiridazinas como moduladores de tirosina cinasa
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
ECSP109953A (es) Derivados de piridazinona
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
BR0312758A (pt) Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
DOP2009000200A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
MX2010005787A (es) Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina.
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
UA113716C2 (xx) Імідазотриазини і імідазопіримідини як інгібітори кінази